11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Patients with suspected bacterial infection at the time screening are eligible for this
study. Patients may participate in this study if they are at least 18 years of age, and most
participants will be receiving care at the clinical practices of the University of
Pennsylvania. Up to 30 subjects will participate in two different imaging cohorts.
The Biodistribution cohort will include up to 5 patients referred from orthopedics who will
undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution
[11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
The Dynamic cohort will include up to 25 patients who will undergo approximately 60 minutes
of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated)
scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected
clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also
undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to
collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with
therapy, the timing of this scan may vary depending on the type of treatment the patient is
receiving.
Patients will also undergo baseline lab tests complete blood count (CBC), C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR) and blood cultures. If these tests are done as
part of clinical standard of care they will not need to be repeated for this study.